查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2005128

急性细菌性皮肤和组织感染疾病市场：按产品类型、给药途径、最终用户、分销管道和治疗方法划分－2026-2032年全球市场预测

Acute Bacterial Skin & Skin Structure Infection Market by Product Type, Route Of Administration, End User, Distribution Channel, Treatment Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，急性细菌性皮肤和皮肤结构感染疾病市场价值将达到 123.5 亿美元，到 2026 年将成长至 135 亿美元，到 2032 年将达到 226.2 亿美元，复合年增长率为 9.02%。

主要市场统计数据
基准年 2025 123.5亿美元
预计年份：2026年 135亿美元
预测年份 2032 226.2亿美元
复合年增长率 (%) 9.02%

简要概述了临床、商业性和政策因素对急性细菌性皮肤和皮肤结构感染疾病。

急性细菌性皮肤感染和结构性皮肤感染疾病呈现出复杂的临床和商业性格局，受到病原体谱系演变、医疗服务环境变化以及监管力度加大的影响。以下概述梳理了当前情势，整合了影响治疗方法选择和取得途径的关键因素，并指出了製药公司、医疗服务提供者和保险公司面临的策略挑战。透过聚焦临床实际情况和市场动态，本分析为商业化、临床开发以及融入医疗体係等方面的精准决策奠定了基础。

抗生素抗药性、向门诊治疗的转变、诊断技术的整合以及基于价值的合约如何全面重塑治疗方法的开发和商业化策略。

在急性细菌性皮肤及皮肤结构感染疾病领域，正在发生多项变革性变化，这些变化正在重新定义治疗方法的研发、应用和报销方式。首先，为应对抗生素抗药性，临床上对标靶药物和合理用药方案的投入不断增加；同时，诊断试剂生产商和治疗药物研发商之间的合作也在加强，以推动基于细菌培养和PCR检测的治疗方法，从而减少频谱抗生素的使用，并维持疗效。

本检验了近期美国关税调整对治疗和诊断药物整个供应链的韧性、筹资策略和商业性竞争的影响。

2025年美国关税环境的变化为急性细菌性皮肤及皮肤结构感染疾病治疗用药品及相关产品的供应链、采购成本和策略采购带来了新的考量。关税政策的变化正在影响门诊和居家照护中使用的进口药品活性成分、无菌生产组件、诊断试剂盒和一次性医疗设备的成本基础。依赖跨境供应链的企业正在采取措施降低关税波动带来的风险，例如重新评估货源、将生产转移到近岸地区以及与具有国内生产能力的契约製造製造商合作。

将产品属性、给药途径、医疗保健环境、分销管道和基于诊断的治疗路径与策略决策联繫起来的详细細項分析。

细分市场层面的洞察揭示了产品类型、给药途径、终端用户环境、分销管道和治疗方法等方面的显着趋势，每种因素都对药物的研发和商业化产生独特的影响。根据产品类型，市场细分为品牌抗生素、非专利抗生素和新药，其中非专利抗生素进一步细分为头孢菌素类、林可酰胺类、大环内酯类和青霉素类。这凸显了製定生命週期管理策略的必要性，以便在应对学名药竞争的同时，保护新进入者的市场价值。

区域比较分析突显了美洲、欧洲、中东、非洲和亚太地区在监管、报销、供应链和临床实践因素方面的差异。

区域趋势影响临床实践、法规环境和商业性准入，并对相关人员如何优先考虑投资和分配资源产生重大影响。在美洲，医疗保健系统优先考虑快速获得有效的门诊服务，并已实施影响药物采用决策的药物管理框架。私人和公共保险公司越来越要求提供真实世界疗效和成本节约的证据，这迫使製造商投资于本地卫生经济数据集和医疗服务提供者参与计画。同时，供应链挑战和关税影响正在影响住院和门诊管道的製造地选择和采购政策。

成熟企业、专业研发公司、诊断药物创新者和生产合作伙伴如何透过合作、证据生成和商业化的协同效应重建其竞争优势。

此治疗领域的竞争动态由多家成熟的大型製药企业、中小型专科药物研发公司、诊断服务提供者和契约製造组织（CMO）组成，它们各自为价值链贡献着不同的优势。大型成熟公司凭藉其庞大的商业基础设施、大规模的临床网络以及在应对复杂监管环境方面的丰富经验，持续维护其自有品牌产品组合。同时，专科药物研发公司则专注于差异化的作用机制、快速的研发週期以及针对特定适应症的治疗，致力于解决抗药性病原体和未被满足的医疗需求。

为整合诊断、加强供应链、优化全通路存取以及与循证和基于价值的支付预期保持一致，提出切实可行的优先建议。

产业领导者应采取多管齐下的策略，将产品开发、临床证据和商业性执行与不断变化的医疗保健和政策环境相协调。首先，应优先考虑诊断整合，透过与实验室和即时检测公司建立伙伴关係，支持基于培养和PCR的治疗路径。及时、基于诊断的决策能够增强对医疗服务提供者和支付方的价值提案。同时，应投资于真实世界数据（REW）项目，收集门诊手术中心、家庭医疗保健机构和医院的治疗结果，以支持关于缩短住院时间、降低再入院率和提高患者满意度的说法。

我们将透过整合策略挑战，推动永续的医疗服务取得和临床影响，并专注于以诊断技术为驱动的医疗保健、具韧性的供应链和实证商业策略。

总之，由于抗生素抗药性、门诊治疗的普及、诊断技术的进步以及采购压力的变化，急性细菌性皮肤及皮肤结构感染疾病领域正处于转折点。这些因素为具有明确临床差异的新型药物以及诊断和治疗手段的及时策略性组合创造了机会，从而使治疗决策能够基于细菌培养和PCR检测结果。同时，价格调整、供应链日益复杂以及医保报销预期凸显了製定稳健的产业计画和循证商业性策略的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：急性细菌性皮肤及皮肤组织感染疾病市场：依产品类型划分

  • 品牌抗生素
  • 非专利抗生素
    • 头孢菌素
    • 林可酰胺
    • 大环内酯类
    • 青霉素
  • 新药

第九章：急性细菌性皮肤及皮肤组织感染疾病市场：依给药途径划分

  • 静脉
  • 口服
  • 外用

第十章：急性细菌性皮肤及皮肤组织感染疾病市场：依最终使用者划分

  • 门诊手术中心
  • 家庭医疗保健设施
  • 医院

第十一章：急性细菌性皮肤及皮肤组织感染疾病市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：急性细菌性皮肤及皮肤组织感染疾病，依治疗方法。

  • 经验性治疗
  • 标靶治疗
    • 根据培养结果进行治疗
    • 基于PCR的治疗

第十三章：急性细菌性皮肤及皮肤组织感染疾病市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：急性细菌性皮肤及皮肤组织感染疾病市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：急性细菌性皮肤及皮肤组织感染疾病市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国急性细菌性皮肤及感染疾病市场

第十七章：中国急性细菌性皮肤及感染疾病市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc
  • Basilea Pharmaceutica Ltd
  • Bayer AG
  • Cipher Pharmaceuticals Inc
  • Cipla Limited
  • Cumberland Pharmaceuticals Inc
  • Dr. Reddy's Laboratories Ltd
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd
  • Lupin Limited
  • Melinta Therapeutics LLC
  • Menarini Group
  • Merck & Co. Inc
  • Nabriva Therapeutics plc
  • Novartis AG
  • Paratek Pharmaceuticals Inc
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc
  • Zydus Lifesciences Limited
Product Code: MRR-B16853776E4F

The Acute Bacterial Skin & Skin Structure Infection Market was valued at USD 12.35 billion in 2025 and is projected to grow to USD 13.50 billion in 2026, with a CAGR of 9.02%, reaching USD 22.62 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.35 billion
Estimated Year [2026] USD 13.50 billion
Forecast Year [2032] USD 22.62 billion
CAGR (%) 9.02%

A concise orientation to the clinical, commercial, and policy drivers reshaping treatment pathways and strategic priorities in acute bacterial skin and skin structure infections

Acute bacterial skin and skin structure infections present a complex clinical and commercial landscape shaped by evolving pathogen profiles, shifting care settings, and heightened regulatory scrutiny. The introduction below frames the current environment, synthesizes key drivers influencing therapeutic selection and access, and clarifies the strategic stakes for manufacturers, providers, and payers. By centering on clinical realities and market dynamics, this analysis establishes the foundation for targeted decision making across commercialization, clinical development, and health system integration.

Clinically, the incidence and diversity of causative organisms have driven renewed attention to rapid diagnostics, antibiotic stewardship, and novel therapeutic approaches that balance efficacy with resistance mitigation. Concurrently, care delivery has migrated in part from inpatient wards to ambulatory surgical centers and home healthcare settings, influencing formulary decisions, administration routes, and the relative importance of oral versus intravenous options. These shifts underscore the need for adaptable commercial strategies that align product attributes with end-user workflows and procurement mechanisms.

From a regulatory and reimbursement standpoint, stakeholders face increasing pressure to demonstrate value in the form of improved outcomes, reduced hospital stays, and lower overall costs of care. This pressure amplifies the importance of differentiated clinical evidence, real-world performance data, and clear positioning against existing branded and generic antibiotics. The ensuing sections build on this introduction to outline transformative market shifts, tariff impacts, segmentation intelligence, regional nuances, competitive positioning, actionable recommendations, and the methodology underpinning the analysis.

How antimicrobial resistance, care migration to outpatient settings, diagnostics integration, and value based contracting are collectively reshaping therapeutic development and commercialization strategies

The landscape for acute bacterial skin and skin structure infections is undergoing several transformative shifts that will redefine how therapies are developed, delivered, and reimbursed. First, the clinical imperative to counteract antimicrobial resistance has intensified investment in targeted agents and stewardship programs, prompting greater collaboration between diagnostics firms and therapeutics developers to enable culture guided and PCR guided treatment approaches that reduce broad-spectrum exposure and preserve efficacy.

Concurrently, care delivery is transitioning toward outpatient and home-based models, elevating the importance of route of administration in commercial planning. Intravenous options maintain a role for severe presentations, but oral and topical formulations are gaining prominence for their potential to shorten hospital stays and support ambulatory care pathways. This reorientation affects procurement channels and necessitates engagement with hospital pharmacies, retail and online pharmacies, and home healthcare providers to ensure seamless access.

Economically and operationally, payers are increasingly focused on value-based contracting and outcomes-based reimbursement, incentivizing manufacturers to demonstrate tangible reductions in length of stay, readmissions, and overall treatment costs. In parallel, regulatory frameworks are emphasizing accelerated development pathways for novel agents that address unmet needs, while also requiring robust post-marketing surveillance. Taken together, these shifts demand cross-functional strategies that integrate clinical evidence generation, diagnostics partnerships, and agile commercial models to capture emerging opportunities.

Examining how recent United States tariff adjustments influence supply chain resilience, sourcing strategies, and commercial competitiveness across therapeutics and diagnostics supply chains

The evolving tariff environment of the United States in 2025 has introduced new considerations for the supply chain, procurement costs, and strategic sourcing for therapeutics and ancillary products relevant to treatment of acute bacterial skin and skin structure infections. Tariff policy changes have influenced the cost base for imported active pharmaceutical ingredients, sterile manufacturing components, diagnostic kits, and single-use devices used in outpatient and home-care administration. Companies that rely on cross-border supply chains have responded by reassessing origins of supply, nearshoring production, and engaging contract manufacturers with domestic capabilities to mitigate exposure to tariff volatility.

In response, firms have prioritized supply chain resilience through diversified sourcing strategies and strengthened supplier agreements that include contingency planning for tariff-related disruptions. These measures have implications for pricing negotiations, procurement cycles in hospital pharmacies and retail channels, and the relative competitiveness of certain product types, particularly those for which manufacturing complexity or raw material sourcing is concentrated in specific geographies. Diagnostics manufacturers and distributors have likewise adapted their channel strategies to preserve access to culture and PCR guided testing modalities amid shifting import costs.

Although tariffs influence cost structures, they also catalyze strategic investments in local manufacturing capacity and vertically integrated models that can buffer commercial programs from policy shifts. As a result, stakeholders are balancing near-term operational adaptations with longer-term capital planning aimed at securing supply continuity, protecting margin, and maintaining timely patient access to both therapeutics and diagnostics across inpatient and outpatient settings.

Detailed segmentation intelligence that aligns product attributes, administration routes, care settings, distribution channels, and diagnostics driven treatment pathways to strategic decision making

Segment-level insights reveal differentiated dynamics across product types, administration routes, end-user settings, distribution channels, and treatment approaches, each carrying distinct implications for development and commercialization. Based on Product Type, market is studied across Branded Antibiotics, Generic Antibiotics, and Novel Agents, with Generic Antibiotics further studied across Cephalosporins, Lincosamides, Macrolides, and Penicillins, which underscores the need for lifecycle management strategies that address generic competition while protecting niche value for novel entrants.

Based on Route Of Administration, market is studied across Intravenous, Oral, and Topical, and the choice among these influences clinical adoption, patient preference, and administration costs; oral agents and topical formulations increasingly serve as enablers for outpatient transition, while intravenous therapies remain essential for severe infections. Based on End User, market is studied across Ambulatory Surgical Centers, Home Healthcare Settings, and Hospitals, emphasizing that engagement strategies must adapt to procurement behaviors, clinical workflows, and reimbursement profiles unique to each setting.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies, which highlights the growing importance of omnichannel access and digital fulfillment for outpatient regimens. Finally, Based on Treatment Type, market is studied across Empiric Treatment and Targeted Treatment, with Targeted Treatment further studied across Culture Guided and Pcr Guided approaches; this segmentation points to a bifurcation between broad empiric therapies and precision-driven strategies that leverage diagnostics to optimize outcomes. Together, these segment lenses enable stakeholders to align product development, evidence generation, and channel strategies with clinical realities and procurement behaviors.

Comparative regional analysis highlighting distinct regulatory, reimbursement, supply chain, and clinical practice drivers across the Americas, Europe Middle East and Africa, and Asia Pacific

Regional dynamics shape clinical practice, regulatory environments, and commercial access in ways that materially affect how stakeholders prioritize investments and allocate resources. In the Americas, health systems emphasize rapid access to effective outpatient therapies and have implemented stewardship frameworks that influence formulary decisions; private and public payers increasingly demand evidence of real-world outcomes and cost offsets, prompting manufacturers to invest in local health economics datasets and provider engagement programs. Meanwhile, supply chain considerations and tariff impacts influence manufacturing footprint decisions and procurement preferences across both inpatient and outpatient channels.

In Europe, Middle East & Africa, heterogeneity in regulatory pathways, reimbursement models, and clinical practice patterns requires tailored market entry strategies. Many countries in this region maintain robust stewardship programs alongside national procurement mechanisms, which can favor therapeutics and diagnostics that demonstrate clear comparative effectiveness and cost containment. Emerging economies within the region are expanding access to outpatient care and home health services, creating opportunities for oral and topical therapies, while also presenting logistical challenges related to cold chain and distribution.

The Asia-Pacific region presents a mix of high-volume markets with rapid adoption of novel diagnostics and digital health tools, alongside jurisdictions with distinct regulatory timelines and pricing pressures. Investments in local clinical research and manufacturing capacity are common, and partnerships with regional distributors or contract manufacturers often accelerate market access. Across all regions, stakeholders should prioritize localized evidence generation, payer engagement, and supply chain strategies that reflect regional policy, clinical practice, and procurement realities to ensure sustainable access and adoption.

How incumbents, specialty developers, diagnostics innovators, and manufacturing partners are reshaping competitive advantages through collaboration, evidence generation, and commercialization synergies

Competitive dynamics in this therapeutic area reflect a mix of established large pharmaceutical firms, smaller specialty developers, diagnostics providers, and contract manufacturing organizations, each contributing different strengths to the value chain. Large incumbent companies continue to leverage broad commercial infrastructures, extensive clinical networks, and experience navigating complex regulatory landscapes to sustain branded product portfolios, whereas specialty developers focus on differentiated mechanisms of action, rapid development cycles, and targeted niche indications to address resistant pathogens and unmet clinical needs.

Diagnostic companies and clinical laboratories have become strategic partners in enabling targeted treatment approaches; their ability to deliver timely culture guided and PCR guided results directly affects prescribing behavior and the commercial trajectory of associated therapeutics. Contract development and manufacturing organizations play an increasingly critical role in scaling production for injectable therapies and in supporting formulation transitions from intravenous to more patient-friendly routes of administration.

Strategic alliances, licensing deals, and co-promotion agreements are prevalent as companies seek to combine strengths in discovery, development, and market access. Across the competitive landscape, differentiation now hinges on robust real-world evidence, integrated diagnostic solutions, and value-based contracting capabilities. For organizations planning entry or expansion, aligning clinical differentiation with pragmatic commercialization plans and diagnostic partnerships will be essential to secure preferential positioning among providers and payers.

Practical and prioritized recommendations for integrating diagnostics, strengthening supply chains, optimizing omnichannel access, and aligning evidence generation with value based payment expectations

Industry leaders should adopt a multi-pronged strategy that aligns product development, clinical evidence, and commercial execution to the changing care and policy environment. First, prioritize diagnostics integration by establishing partnerships with laboratories and point-of-care testing firms to support culture guided and PCR guided treatment pathways; demonstrating timely diagnostic-driven decision making will strengthen value propositions with providers and payers. Concurrently, invest in real-world evidence programs that capture outcomes across Ambulatory Surgical Centers, Home Healthcare Settings, and Hospitals to substantiate claims about reduced length of stay, lower readmissions, and improved patient satisfaction.

Second, adapt commercialization models to omnichannel distribution frameworks that include hospital pharmacies, online pharmacies, and retail pharmacies while ensuring seamless fulfillment and patient support services for oral and topical therapies. Consider flexible pricing and value-based contracting arrangements that align reimbursement with measurable patient outcomes. Third, enhance supply chain resilience by diversifying suppliers of active pharmaceutical ingredients and considering nearshoring or regional manufacturing partnerships to mitigate tariff exposure and logistical risk.

Finally, integrate lifecycle management tactics that manage generic competition within Cephalosporins, Lincosamides, Macrolides, and Penicillins while protecting the commercial potential of novel agents through targeted clinical differentiation, post-marketing surveillance, and proactive stakeholder engagement. By orchestrating these initiatives, organizations can drive adoption, protect margin, and demonstrate continuous value to payers, providers, and patients.

The research underpinning this analysis employed a mixed-methods approach designed to triangulate clinical, commercial, and policy inputs to produce actionable insights. Primary research included structured interviews with clinicians across hospital, ambulatory, and home healthcare settings, procurement and formulary decision-makers, diagnostics laboratory directors, and senior commercial executives from developers and distributors. These conversations provided qualitative depth on prescribing behavior, treatment pathways, and procurement criteria, and were complemented by targeted expert panels to validate emerging trends and scenario implications.

Secondary research integrated peer-reviewed clinical literature, regulatory guidance documents, product labels, and published clinical trial results to ground therapeutic and diagnostic assessments in evidence. Industry databases and public filings were examined to map product pipelines, approval timelines, and patent landscapes where available. Data triangulation was applied to reconcile differences across sources, and sensitivity checks were performed to ensure conclusions remained robust under alternative assumptions about care setting adoption and supply chain responses.

Finally, analytical frameworks were used to synthesize findings into strategic implications and recommendations. These frameworks emphasized alignment across clinical differentiation, diagnostics enabling targeted treatment, channel strategy, and regional access planning, ensuring that the conclusions are actionable for developers, payers, and health systems seeking to navigate the evolving acute bacterial skin and skin structure infection environment.

A synthesis of strategic imperatives emphasizing diagnostics enabled care, resilient supply chains, and evidence based commercial strategies to drive sustainable access and clinical impact

In conclusion, the acute bacterial skin and skin structure infection arena is at an inflection point driven by antimicrobial resistance, shifts to outpatient care, diagnostic advances, and evolving procurement pressures. These forces are creating opportunities for novel agents that offer clear clinical differentiation and for strategic combinations of therapeutics with timely diagnostics that enable culture guided and PCR guided treatment decisions. At the same time, tariff developments, supply chain complexities, and reimbursement expectations underscore the need for resilient operational planning and evidence-centered commercial approaches.

Stakeholders that succeed will be those that integrate clinical evidence generation with pragmatic commercialization strategies-aligning product attributes to route of administration preferences, end-user workflows across Ambulatory Surgical Centers, Home Healthcare Settings, and Hospitals, and distribution pathways spanning Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. By investing in diagnostics partnerships, real-world evidence, and flexible supply chain models, organizations can accelerate adoption, defend margins, and contribute meaningfully to improved patient outcomes. The pathway forward requires coordination across R&D, commercial, regulatory, and supply chain functions to turn insights into measurable impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Bacterial Skin & Skin Structure Infection Market, by Product Type

  • 8.1. Branded Antibiotics
  • 8.2. Generic Antibiotics
    • 8.2.1. Cephalosporins
    • 8.2.2. Lincosamides
    • 8.2.3. Macrolides
    • 8.2.4. Penicillins
  • 8.3. Novel Agents

9. Acute Bacterial Skin & Skin Structure Infection Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Topical

10. Acute Bacterial Skin & Skin Structure Infection Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Home Healthcare Settings
  • 10.3. Hospitals

11. Acute Bacterial Skin & Skin Structure Infection Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Acute Bacterial Skin & Skin Structure Infection Market, by Treatment Type

  • 12.1. Empiric Treatment
  • 12.2. Targeted Treatment
    • 12.2.1. Culture Guided
    • 12.2.2. Pcr Guided

13. Acute Bacterial Skin & Skin Structure Infection Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Acute Bacterial Skin & Skin Structure Infection Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Acute Bacterial Skin & Skin Structure Infection Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Acute Bacterial Skin & Skin Structure Infection Market

17. China Acute Bacterial Skin & Skin Structure Infection Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc
  • 18.6. Basilea Pharmaceutica Ltd
  • 18.7. Bayer AG
  • 18.8. Cipher Pharmaceuticals Inc
  • 18.9. Cipla Limited
  • 18.10. Cumberland Pharmaceuticals Inc
  • 18.11. Dr. Reddy's Laboratories Ltd
  • 18.12. GlaxoSmithKline plc
  • 18.13. Glenmark Pharmaceuticals Ltd
  • 18.14. Lupin Limited
  • 18.15. Melinta Therapeutics LLC
  • 18.16. Menarini Group
  • 18.17. Merck & Co. Inc
  • 18.18. Nabriva Therapeutics plc
  • 18.19. Novartis AG
  • 18.20. Paratek Pharmaceuticals Inc
  • 18.21. Pfizer Inc
  • 18.22. Teva Pharmaceutical Industries Ltd
  • 18.23. Viatris Inc
  • 18.24. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY BRANDED ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY BRANDED ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY BRANDED ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY LINCOSAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY LINCOSAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY LINCOSAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY NOVEL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY NOVEL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY NOVEL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY EMPIRIC TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY EMPIRIC TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY EMPIRIC TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CULTURE GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CULTURE GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY CULTURE GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PCR GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PCR GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PCR GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. GCC ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. G7 ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NATO ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY GENERIC ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTION MARKET SIZE, BY TARGETED TREATMENT, 2018-2032 (USD MILLION)